Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

Retina

Volumn 27, Issue 9, 2007, Pages 1187-1195

  Soheilian, Masoud ^a,b,d   Ramezani, Alireza ^a,b   Bijanzadeh, Bijan ^a,b   Yaseri, Mehdi ^a   Ahmadieh, Hamid ^a,b   Dehghan, Mohammad H ^a,b   Azarmina, Mohsen ^a,b   Moradian, Siamak ^a,b   Tabatabaei, Homa ^a,b   Peyman, Gholam A ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Negah Eye Hospital   (Iran)

^c UNIVERSITY OF ARIZONA   (United States)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bevacizumab; Clinically significant diabetic macular edema; Diabetic retinopathy; Macular laser photocoagulation; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ANTERIOR CHAMBER REACTION; ARTICLE; BLOOD PRESSURE VARIABILITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR HYPERTENSION; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RETINA DETACHMENT; RETINA MACULA LUTEA; SIDE EFFECT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 36749103212     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31815ec261     Document Type: Article

References (41)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
2. Hardy RA, Crawford JB. Retina. In: Vaughn D, Asbury T, Riordan-Eva P, eds. General Ophthalmology. 15th ed. Stamford, CT: Appleton & Lange; 1999:178-199.
3. Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macular edema. Surv Ophthalmol 2004;49:470-490.
4. Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I. Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993;115:64-67.
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
6. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98:1594-1602.
7. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-2049.
8. Massin P, Aurden F, Houchine B, Erginy A. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-225.
9. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
10. Jonas JB, Kamppeter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207.
11. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-630.
12. Cunningham ET Jr, Adamis AP, Altaweel M, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
13. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-1712.
14. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
15. Starita C, Patel M, Katz B, Adamis AP. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen®) in diabetic retinopathy. Dev Ophthalmol 2007;39:122-148.
16. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci 2005;46:4336-4341.
17. Gardner TW, Antonetti DA, Barber AJ, et al. Penn State Retina Research Group. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47:S253-S256.
18. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-232.
19. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003;110:1690-1696.
20. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005;112:806-816.
21. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
22. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-1695.e15.
23. Pocock SJ. Clinical Trials: A Practical Approach. Great Britain: John Wiley & Sons; 1990:148-149.
24. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-1547.
25. Gillies MC. What we don't know about Avastin might hurt us. Arch Ophthalmol 2006;124:1478-1479.
26. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004;242:91-101.
27. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
28. Jin K, Zhu Y, Sun Y, et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99:11946-11950.
29. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-138.
30. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-926.
31. Beer PM, Bakri SJ. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686.
32. Nelson ML, Tentant MTS. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003:23;686-691.
33. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006;142:794-799.
34. Diabetic Retinopathy Clinical Research Network. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema. Version 4.0. 2005:13; http://www.t1diabetes.nih.gov/ investigator/resources/Protocol_Protocol_B.pdf.
35. Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004;88:1173-1179.
36. Thompson MJ, Ip MS. Diabetic macular edema: a review of past, present, and future therapies. Int Ophthalmol Clin 2004;44:51-67.
37. Christoforidis JB, D'Amico DJ. Surgical and other treatments of diabetic macular edema: an update. Int Ophthalmol Clin 2004;44:139-160.
38. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
39. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688.
40. Adamis AP, Altaweel M, Bressler NM, et al. Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-28.
41. Schmid KE, Neumaier-Ammerer B, Stolba U, Binder S. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 2006;244:1446-1452.